Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study

Background Linezolid is recommended for treating drug-resistant tuberculosis. Adverse events are a concern to prescribers but have not been systematically studied at the standard dose, and the relationship between linezolid exposure and clinical toxicity is not completely elucidated. Patients and Methods We conducted an observational cohort study to describe the incidence and determinants of linezolid toxicity, and to determine a drug exposure threshold for toxicity, among patients with rifampicin-resistant tuberculosis in South Africa. Linezolid exposures were estimated from a population pharmacokinetic model. Mixed-effects modelling was used to analyse toxicity outcomes. Results 151 participants, 63% HIV-positive, were enrolled and followed for a median of 86 weeks. Linezolid was permanently discontinued for toxicity in 32 (21%) participants. Grade 3 or 4 linezolid-associated adverse events occurred in 21 (14%) participants. Mean haemoglobin concentrations increased with time on treatment (0.03 g/dL per week; 95% CI, 0.02 to 0.03). Linezolid trough concentration, male sex, and age (but not HIV-positivity) were independently associated with a decrease in haemoglobin > 2 g/dL. Trough linezolid concentration of 2.5 mg/L or higher resulted in optimal model performance to describe changing haemoglobin and treatment-emergent anaemia (adjusted odds ratio 2.9; 95% CI, 1.3 to 6.8). Single nucleotide polymorphisms 2706A>G and 3010G>A in mitochondrial DNA were not associated with linezolid toxicity. Conclusions Permanent discontinuation of linezolid was common, but linezolid-containing therapy was associated with average improvement in toxicity measures. HIV co-infection was not independently associated with linezolid toxicity. Linezolid trough concentration of 2.5 mg/L should be evaluated as a target for therapeutic drug monitoring.